Mission Therapeutics, a private drug discovery and development company based south of Cambridge, has secured $13,300,000 in new investment capital from investors. The company is focused on selectively targeting deubiquitylating enzymes (DUBs) to treat diseases of high unmet medical need.
This funding round will be pivotal in accelerating the company's innovative work. Mission Therapeutics has established a world-leading platform for the discovery and development of first-in-class, small-molecule drugs specifically designed to target DUBs. These enzymes represent an emerging and increasingly attractive drug class, drawing significant commercial interest and often considered the potential ‘Next Kinase Area’ in drug development. Through this platform, Mission is cultivating a rich pipeline of novel therapeutics with the goal of benefiting patients across diverse therapeutic areas.
The capital raised will be strategically deployed to advance Mission Therapeutics’ pipeline programmes. The company plans to use these funds to further progress its drug discovery and development efforts, specifically supporting its strategy to move programmes through early clinical development. This includes enhancing its patient selection strategy, which is designed to improve the likelihood of demonstrating early signs of efficacy for its treatments.
Mission Therapeutics is supported by a leadership team bringing a wealth of international commercial and scientific experience to its operations. The company also maintains strong collaborative links with prominent academic and research centers, including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge. This latest investment underscores the potential of its DUB-targeting approach and positions Mission Therapeutics for continued growth as it works to bring its novel therapies to patients.
